ASX biotech stock Mesoblast Ltd (ASX: MSB) has pulled back sharply in 2026, but some investors may see the weakness as a potential buying opportunity.
After climbing above $3 in early January, the ASX biotech stock has largely trended lower and is now down around 27% year to date at the time of writing.
Biotech shares are often volatile, and Mesoblast is no exception. But despite the recent sell-off, several factors suggest the company could still have substantial upside ahead.
Here are three reasons why this ASX biotech stock may be worth a closer look.
Image source: Getty Images
Ryoncil could drive cash flow growth
One of the biggest positives for Mesoblast is the growing commercial opportunity surrounding Ryoncil. The company believes sales from the therapy alone could eventually support earnings generation and cash flow positive operations, which would mark a major milestone for the biotech business.
That is significant because many biotechnology companies remain heavily reliant on external funding for years before becoming commercially sustainable.
If Mesoblast can successfully scale Ryoncil sales, investor confidence in the company's long-term financial position could improve substantially. For a speculative ASX biotech stock, the prospect of sustainable cash flow generation is a major advantage.
Multiple growth opportunities remain
Mesoblast's pipeline also extends well beyond a single product. The company says new product approvals are now well advanced in areas including heart failure and chronic lower back pain. Both markets represent potentially enormous long-term commercial opportunities.
If future regulatory approvals are achieved, Mesoblast could significantly expand revenue streams over the coming years.
Investors are increasingly focusing on the broader pipeline potential rather than viewing the company as dependent on one treatment outcome. Importantly, expanding revenues and commercial diversification may also help reduce risk over time.
For investors comfortable with biotech volatility, the company's pipeline could provide considerable upside leverage.
Broker optimism is growing
Analyst sentiment toward Mesoblast has also become increasingly positive despite recent share price weakness. TradingView data shows that all seven analysts covering the ASX biotech stock rate it a strong buy, with an average 12-month price target of $4.12, which suggests 105% upside.
Bell Potter last week reaffirmed its speculative buy rating on the ASX biotech stock with a $4.50 price target. That target suggests potential upside of more than 120% from current trading levels. The broker's bullish stance reflects growing confidence in Mesoblast's commercial outlook and product pipeline progress.
If investor sentiment toward healthcare and biotech shares improves more broadly, Mesoblast could benefit strongly from renewed market enthusiasm.
Risks remain
Of course, investing in ASX biotech stocks still carries elevated risks.
Mesoblast remains exposed to regulatory uncertainty, clinical trial outcomes and commercial execution challenges. Funding requirements and share price volatility also remain important considerations for investors.
A weaker-than-expected product rollout or regulatory setback could significantly impact sentiment.
Still, after a sharp 2026 decline, some investors may believe the risk-reward profile is becoming increasingly attractive.
With commercial revenues building, multiple approval pathways advancing and broker confidence strengthening, Mesoblast could be one ASX biotech stock worth watching closely.
